Cargando…
2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections (LRTI) during infancy worldwide. High cord blood (CB) concentrations of anti-RSV neutralizing antibody (nAb) may attenuate, delay, or prevent infant infection. We report RSV A and B nAb conce...
Autores principales: | Domachowske, Joseph B, Bianco, Veronique, Ceballos, Ana, Cousin, Luis, D’Andrea, Ulises, Dieussaert, Ilse, Englund, Janet A, Gandhi, Sanjay, Haars, Gerco, Jose, Lisa, Klein, Nicola, Marie. Langley, Joanne, Leach, Amanda, Madhi, Shabir A, Maleux, Koen, Lien-Anh Nguyen, Thi, Puthanakit, Thanyawee, Silas, Peter, Stoszek, Sonia K, Tangsathapornpong, Auchara, Teeratakulpisarn, Jamaree, Virta, Miia, Zaman, Khalequ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808773/ http://dx.doi.org/10.1093/ofid/ofz359.160 |
Ejemplares similares
-
Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings( )
por: Langley, Joanne M, et al.
Publicado: (2022) -
Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children
por: Englund, Janet A, et al.
Publicado: (2023) -
1506. Burden of Respiratory Syncytial Virus (RSV) and Other Lower Respiratory Tract Viral Infections During the First Two Years of Life: a Prospective Study
por: Madhi, Shabir A, et al.
Publicado: (2020) -
The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
por: Chantasrisawad, Napaporn, et al.
Publicado: (2023) -
Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial
por: Shin, Jonghoon, et al.
Publicado: (2019)